Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.69 |
| ▸ | CCR8 | P51685 | 3/20 | 0.69 |
| ▸ | CCR5 | P51681 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.46 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185654 | 0.90 | CCR1 (0.50) | CCR1CCR8CCR5SLC40A1PDGFRB | |
| SCHEMBL17921313 | 0.83 | MAPT (0.49) | CCR1CCR8CCR5L3MBTL1SLC40A1 | |
| SCHEMBL182930 | 0.83 | CCR1 (1.00) | CCR1CCR8CCR5L3MBTL1PSMD14 | |
| SCHEMBL29563986 | 0.83 | CCR1 (1.00) | CCR1CCR8CCR5L3MBTL1PSMD14 | |
| SCHEMBL9605472 | 0.83 | CCR1 (0.45) | CCR1CCR8CCR5L3MBTL1SLC40A1 | |
| Hydrochloric Acid SCHEMBL4612883 | 0.82 | SLC40A1 (0.47) | CCR1CCR8CCR5SLC40A1PDGFRB | |
| Water SCHEMBL23927104 | 0.81 | CCR1 (0.95) | CCR1CCR8CCR5L3MBTL1PSMD14 | |
| SCHEMBL4890980 | 0.81 | CCR1 (0.95) | CCR1CCR8CCR5L3MBTL1PSMD14 | |
| SCHEMBL6744043 | 0.81 | CCR1 (0.95) | CCR1CCR8CCR5L3MBTL1PSMD14 | |
| SCHEMBL31493927 | 0.81 | CCR1 (0.95) | CCR1CCR8CCR5L3MBTL1PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ATHENEX, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230203072-A1 | AIR-STABLE IMIDO ALKYLIDENE COMPLEXES AND USE THEREOF IN OLEFIN METATHESIS REACTIONS | VERBIO SE (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20180201558-A1 | PROCESS FOR PRODUCTION OF D-SORBITOL | DSM IP ASSETS B.V. (NL) | 2018-07-19 | — | — | US | disclosed |
| US-20180201959-A1 | PRODUCTION OF D-SORBITOL BY HYDROGENATION | DSM IP ASSETS B.V. (NL) | 2018-07-19 | — | — | US | disclosed |
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| US-20180022708-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-01-25 | — | — | US | disclosed |
| US-9789089-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9771328-B2 | Processes for preparing ASK1 inhibitors | GILEAD SCIENCES, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170233350-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | GILEAD SCIENCES, INC. | 2017-08-17 | — | — | US | disclosed |
| US-9586933-B2 | Processes for preparing ASK1 inhibitors | GILEAD SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160244430-A1 | Processes for preparing ASK1 inhibitors | GILEAD SCIENCES, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9220710-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150307538-A1 | USE OF THERMALLY-TREATED SUPPORTED COBALT CATALYSTS COMPRISING A POLYCYCLIC AROMATIC STRUCTURE CONSISTING OF NITROGEN LIGANDS FOR HYROGENATING AROMATIC NITRO COMPOUNDS | EVONIK DEGUSSA GMBH (DE) | 2015-10-29 | — | — | US | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| WO-2009108766-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER ' S DISEASE | SCHERING CORPORATION (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203072-A1 | AIR-STABLE IMIDO ALKYLIDENE COMPLEXES AND USE THEREOF IN OLEFIN METATHESIS REACTIONS | SOD1, ZRANB2, ZNF277 | CCR1 1790/4885CCR8 1295/4885CCR5 3303/4885 |
| US-20170233350-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | MAP3K1, MAP3K6, MAP3K7 | CCR1 1767/4885CCR8 2109/4885CCR5 2102/4885 |
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | IDO1, IDO2, TDO2 | CCR1 1734/4885CCR8 1967/4885CCR5 1799/4885 |
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | CCR1 258/4885CCR8 690/4885CCR5 27/4885 |
| US-20180201558-A1 | PROCESS FOR PRODUCTION OF D-SORBITOL | SORD, ALDOA, DCXR | CCR1 4485/4885CCR8 4590/4885CCR5 4280/4885 |
| US-20180022708-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | MAP3K1, MAP3K6, MAP3K7 | CCR1 1767/4885CCR8 2109/4885CCR5 2102/4885 |
| US-20180201959-A1 | PRODUCTION OF D-SORBITOL BY HYDROGENATION | SORD, TREH, DCXR | CCR1 4547/4885CCR8 4631/4885CCR5 4139/4885 |
| US-20160244430-A1 | Processes for preparing ASK1 inhibitors | MAP3K1, MAP3K6, MAP3K7 | CCR1 1767/4885CCR8 2109/4885CCR5 2102/4885 |
| US-20150307538-A1 | USE OF THERMALLY-TREATED SUPPORTED COBALT CATALYSTS COMPRISING A POLYCYCLIC AROMATIC STRUCTURE CONSISTING OF NITROGEN LIGANDS FOR HYROGENATING AROMATIC NITRO COMPOUNDS | NUP188, NUP50, NUCB2 | CCR1 1046/4885CCR8 1028/4885CCR5 989/4885 |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | CCR1 258/4885CCR8 690/4885CCR5 27/4885 |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CCR1 4808/4885CCR8 4851/4885CCR5 4183/4885 |
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ABCB1, CYP3A5, CYP3A7 | CCR1 3889/4885CCR8 3420/4885CCR5 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.